drugset / Trial / NCT02180295

A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)

NCT02180295

Phase 3 Withdrawn Merck Sharp & Dohme LLC
RandomizedParallel-groupTriple-blindPrevention

Summary

The study will evaluate the consistency of 3 lots of inactivated VZV vaccine for safety, tolerability, and immunogenicity in healthy adults. The primary hypothesis of the study is that the 3 lots of inactivated vaccine will demonstrate similar immunogenicity at 28 days after the fourth dose.

Timeline

Start
2014-07
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject V212 Vaccine 7.5 iu Subcutaneous

Indications